» Articles » PMID: 16316377

Thrombocytopenia Induced by Nicotinamide in Hemodialysis Patients

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2005 Dec 1
PMID 16316377
Citations 11
Authors
Affiliations
Soon will be listed here.
Citing Articles

Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches.

Anand A, Aoyagi H Medicina (Kaunas). 2023; 59(5).

PMID: 37241191 PMC: 10221414. DOI: 10.3390/medicina59050959.


Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.

Ketteler M, Wiecek A, Rosenkranz A, Ose C, Rekowski J, Lorenz H Nephrol Dial Transplant. 2022; 38(4):982-991.

PMID: 35751625 PMC: 10064978. DOI: 10.1093/ndt/gfac206.


Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial.

Ketteler M, Wiecek A, Rosenkranz A, Pasch A, Rekowski J, Hellmann B Kidney Int Rep. 2021; 6(3):594-604.

PMID: 33732974 PMC: 7938065. DOI: 10.1016/j.ekir.2020.12.012.


Biological Efficacy and Safety of Niacinamide in Patients With ADPKD.

El Ters M, Zhou X, Lepping R, Lu P, Karcher R, Mahnken J Kidney Int Rep. 2020; 5(8):1271-1279.

PMID: 32775826 PMC: 7403550. DOI: 10.1016/j.ekir.2020.06.002.


Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.

Liu X, Yang R, Dai B, Zhang H, Wang J, Ma N Medicine (Baltimore). 2018; 97(12):e0117.

PMID: 29561409 PMC: 5895315. DOI: 10.1097/MD.0000000000010117.